查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1741186

溶瘤病毒治療市場按產品類型、應用、開發階段、通路和地區分類

Oncolytic Virus Therapy Market, By Product Type, By Application , By Development Stage, By Distribution Channel, By Region
出版日期: | 出版商: Coherent Market Insights | 英文 165 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

溶瘤病毒治療市場規模預計在 2025 年為 1,780 萬美元，預計到 2032 年將達到 8,730 萬美元，2025 年至 2032 年的年複合成長率為 25.5%。

報告範圍 報告詳細資訊
基準年 2024 2025年的市場規模 1780萬美元
效能數據 2020-2024 預測期 2025-2032
預測期間：2025年至2032年的年複合成長率 25.50% 2032年價值預測 8730萬美元

溶瘤病毒療法是一種很有前景的癌症治療方法，它利用工程病毒選擇性地靶向和摧毀癌細胞，同時保護健康細胞。病毒性癌症療法的概念可以追溯到 20 世紀初。隨著基因工程的進步，這一領域在 20 世紀 90 年代獲得了發展勢頭，科學家可以修改病毒以增強腫瘤特異性和治療效果。溶瘤病毒可以感染癌細胞，在其中複製，並誘導細胞裂解或刺激針對腫瘤的免疫反應。正在進行的研究和開發重點是最佳化病毒平台、開發聯合治療以及將溶瘤病毒療法的應用擴展到各種癌症類型。學術界、製藥公司和研究機構之間的合作研究有可能推動新型癌症溶瘤病毒療法的開發並推進癌症治療方法。

市場動態

由於病毒工程的進步、對癌症生物學的更好理解、臨床試驗的成功以及對創新癌症治療的需求，全球溶瘤病毒治療市場正經歷強勁成長。此外，對新癌症適應症的探索、改善治療效果的聯合治療、個人化醫療方法以及開發具有增強特性的下一代病毒預計將在不久的將來帶來光明的市場機會。市場趨勢包括病毒治療平台、標靶遞送系統和免疫調節策略的進步，解決了這一領域的製造和商業化挑戰。此外，市場參與者正專注於合作研究開發新藥，預計將推動全球溶瘤病毒治療市場的成長。例如，2023 年 6 月 29 日，後期臨床階段生物製藥公司 Genelux Corporation 和 TVAX Biomedical, Inc. 宣布，美國專利商標局已授予一項專利，要求保護一種將疫苗增強過繼 T 細胞療法與溶瘤病毒輔助性治療相結合的方法。該專利已獨家授權給V2ACT Therapeutics, LLC，該公司是Generax和TVAX為開發和測試V2ACT免疫療法而成立的合資公司。專利到期，為V2ACT免疫療法增加了實質的智慧財產權保護。

然而，有限的臨床證據、給藥和分銷方面的挑戰、治療相關的高成本以及治療的副作用等因素預計將阻礙市場的成長。克服這些挑戰對於最大限度地提高溶瘤病毒療法的療效並使其更廣泛地普及至關重要。

研究的主要特點

  • 本報告對全球溶瘤病毒治療市場進行了詳細分析，並以 2024 年為基準年，展示了預測期 2025-2032 的市場規模和年複合成長率。
  • 它還揭示了不同領域的潛在商機，並說明了該市場的有吸引力的投資提案矩陣。
  • 它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景和主要企業採用的競爭策略的主要考察。
  • 該報告根據公司亮點、產品系列、關鍵亮點、財務表現和策略等參數，對全球溶瘤病毒治療市場的主要企業進行了概述。
  • 本報告的見解將使負責人和企業經營團隊能夠就未來的產品發布、高階市場策略、市場擴張和行銷策略做出明智的決策。
  • 本研究報告針對該產業的各個相關人員，包括投資者、供應商、產品製造商、經銷商、新進業者和財務分析師。
  • 相關人員可以透過全球溶瘤病毒治療市場分析中使用的各種策略矩陣來簡化決策。

目錄

第1章 調查目的與前提條件

  • 研究目標
  • 先決條件
  • 簡稱

第2章 市場展望

  • 報告描述
    • 市場定義和範圍
  • 執行摘要
  • 一致的機會圖（COM）

第3章市場動態、法規與趨勢分析

  • 市場動態
  • 病毒工程的進展
  • 增進對癌症生物學的理解
  • 臨床試驗成功案例
  • 創新癌症治療的需求
  • 治療費用高昂
  • 治療的副作用
  • 尋找新的癌症適應症
  • 結合治療以改善療效
  • 個人化醫療方法
  • 影響分析
  • 監管情景
  • 產品發布/核准
  • PEST分析
  • 波特分析
  • 併購場景

4. 溶瘤病毒治療市場-冠狀病毒（COVID-19）大流行的影響

  • COVID-19流行病學
  • 供需側分析
  • 經濟影響

5. 溶瘤病毒治療市場（依產品類型），2020 年至 2032 年

  • 介紹
  • 單純皰疹病毒
  • 腺病毒
  • 痘苗病毒
  • 呼腸孤病毒
  • 麻疹病毒
  • 其他（新城疫病毒、水痘口炎病毒）

6. 溶瘤病毒療法市場（按應用分類），2020 年至 2032 年

  • 介紹
  • 黑色素瘤
  • 乳癌
  • 頭頸癌
  • 膀胱癌
  • 攝護腺癌
  • 肺癌
  • 其他（結腸癌等）

7. 溶瘤病毒治療市場（依發展階段分類），2020 年至 2032 年

  • 介紹
  • 商業的
  • 管道階段
  • 臨床前
  • 第一階段
  • 第二階段
  • 第三階段

8. 溶瘤病毒治療市場（依通路分類），2020 年至 2032 年

  • 介紹
  • 醫院藥房
  • 零售藥局
  • 網路藥局

9. 溶瘤病毒治療市場（按地區分類），2020 年至 2032 年

  • 介紹
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
    • 東南亞國協
    • 其他亞太地區
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 其他拉丁美洲
  • 中東
    • 海灣合作理事會國家
    • 以色列
    • 其他中東地區
  • 非洲
    • 北非
    • 中部非洲
    • 南非

第10章 競爭格局

  • Amgen Inc.
  • Merck & Co., Inc.
  • Oncolytics BIoTech Inc.
  • Circio Holding ASA
  • Akamis Bio
  • Vyriad, Inc.
  • SillaJen BIoTherapeutics
  • Cold Genesys Inc.
  • Sorrento Therapeutics, Inc.
  • Takara Bio Inc.
  • Replimune Group Inc.
  • Genelux Corporation
  • Synthetic Biologics, Inc
  • Lokon Pharma AB
  • Elicera Therapeutics

第 11 章 章節

  • 調查方法
  • 關於出版商
簡介目錄
Product Code: CMI5916

Oncolytic Virus Therapy Market is estimated to be valued at USD 17.8 Mn in 2025 and is expected to reach USD 87.3 Mn by 2032, growing at a compound annual growth rate (CAGR) of 25.5% from 2025 to 2032.

Report Coverage Report Details
Base Year: 2024 Market Size in 2025: USD 17.8 Mn
Historical Data for: 2020 To 2024 Forecast Period: 2025 To 2032
Forecast Period 2025 to 2032 CAGR: 25.50% 2032 Value Projection: USD 87.3 Mn

Oncolytic virus therapy is a promising approach to cancer treatment that utilizes modified viruses to selectively target and destroy cancer cells while sparing healthy cells. The concept for viruses for cancer treatment dates back to the early 20th century, when researchers observed tumor regression in patients with viral infections. The field gained momentum in the 1990s with advancements in genetic engineering, enabling scientists to modify viruses to enhance the tumor-specificity and therapeutic efficacy. Oncolytic viruses can infect cancer cells, replicate within them, and induce cell lysis or stimulate immune responses against the tumor. Ongoing research focuses on optimizing viral platforms, developing combination therapies, and expanding the application of oncolytic virus therapy to various cancer types. Collaborations between academia, pharmaceutical companies, and research institutions drive the development of novel oncolytic virus therapies and hold promise for advancing cancer treatment approaches.

Market Dynamics:

The global oncolytic virus therapy market is witnessing strong growth on account of growing advancements in viral engineering, increasing understanding of cancer biology, successful clinical trial results, and the need for innovative cancer treatments. Moreover, exploring new cancer indications, combining therapies for improved outcomes, personalized medicine approaches, and the development of next-generation viruses with enhanced characteristics are expected to bring bright market opportunities in the near future. The market trends include advancements in virotherapy platforms, targeted delivery systems, immune modulation strategies, and addressing manufacturing and commercialization challenges in the field. Moreover, market players are focused on developing novel drugs by collaborating, which is expected to drive the growth of global oncolytic virus therapy market. For instance, on June 29, 2023, Genelux Corporation, a late clinical-stage biopharmaceutical company, and TVAX Biomedical, Inc., a late clinical-stage biopharmaceutical company, announced that the U.S. Patent and Trademark Office granted a patent claiming methods of combining vaccine-enhanced adoptive T cell therapy with oncolytic virus adjunct therapy. The patent has been exclusively licensed to V2ACT Therapeutics, LLC, a joint venture between Genelux and TVAX that was established for the purpose of developing and testing V2ACT immunotherapy. The patent expiry, prior to any patent term extension, will be in 2036 and will add substantial intellectual property protection for V2ACT immunotherapy.

However, limited clinical evidence, delivery and distribution challenges, high costs associated with treatment, and side effects of treatment are expected to hamper market growth. Overcoming these challenges is essential to maximizing the efficiency and broader adoption of oncolytic virus therapies.

Key features of the study:

  • This report provides in-depth analysis of the global oncolytic virus therapy market, and provides market size (US$ Mn) and compound annual growth rate (CAGR %) for the forecast period 2025-2032, considering 2024 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global oncolytic virus therapy market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study Amgen Inc., Merck & Co., Inc., Oncolytics Biotech Inc., Circio Holding ASA, Akamis Bio, Vyriad, Inc., SillaJen Biotherapeutics, Cold Genesys Inc., Sorrento Therapeutics, Inc., Takara Bio Inc., Replimune Group Inc., Genelux Corporation, Synthetic Biologics, Inc., Lokon Pharma AB, and Elicera Therapeutics.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global oncolytic virus therapy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global oncolytic virus therapy market

Detailed Segmentation:

  • Global Oncolytic Virus Therapy Market, By Product Type:
    • Herpes simplex virus
    • Adenovirus
    • Vaccinia virus
    • Reovirus
    • Measles virus
    • Others (Newcastle disease virus, Vesicular stomatitis virus)
  • Global Oncolytic Virus Therapy Market, By Application:
    • Melanoma
    • Breast cancer
    • Head and neck cancer
    • Bladder Cancer
    • Prostate Cancer
    • Lung Cancer
    • Others (Colorectal Cancer, and among Others)
  • Global Oncolytic Virus Therapy Market, By Development Stage:
    • Commercial
    • Pipeline Phase
    • Pre-clinical
    • Phase I
    • Phase II
    • Phase III
  • Global Oncolytic Virus Therapy Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Oncolytic Virus Therapy Market, By Region:
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East and Africa
  • Company Profiles:
    • Amgen Inc.
    • Merck & Co., Inc.
    • Oncolytics Biotech Inc.
    • Circio Holding ASA
    • Akamis Bio
    • Vyriad, Inc.
    • SillaJen Biotherapeutics
    • Cold Genesys Inc.
    • Sorrento Therapeutics, Inc.
    • Takara Bio Inc.
    • Replimune Group Inc.
    • Genelux Corporation
    • Synthetic Biologics, Inc.
    • Lokon Pharma AB
    • Elicera Therapeutics

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Global Oncolytic Virus Therapy Market, By Product Type
    • Global Oncolytic Virus Therapy Market, By Application
    • Global Oncolytic Virus Therapy Market, By Development Stage
    • Global Oncolytic Virus Therapy Market, By Distribution Channel
    • Global Oncolytic Virus Therapy Market, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
  • Advancements in Viral Engineering
  • Increasing Understanding of Cancer Biology
  • Successful Clinical Trial Results
  • Need for Innovative Cancer Treatments
    • Restraints
  • High cost associated with treatment
  • Side effects of treatment
    • Opportunities
  • Exploring new cancer indications
  • Combining therapies for improved outcomes
  • Personalized medicine approaches
  • Impact Analysis
  • Key Highlights
  • Regulatory Scenario
  • Product launch/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Merger and Acquisition Scenario

4. Oncolytic Virus Therapy Market - Impact of Coronavirus (COVID-19) Pandemic

  • COVID-19 Epidemiology
  • Supply Side and Demand Side Analysis
  • Economic Impact

5. Oncolytic Virus Therapy Market , By Product Type, 2020-2032, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021-2032
    • Segment Trends
  • Herpes Simplex Virus
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
  • Adenovirus
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
  • Vaccinia virus
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
  • Reovirus
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
  • Measles virus
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
  • Others (Newcastle disease virus, Vesicular stomatitis virus)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)

6. Oncolytic Virus Therapy Market, By Application, 2020-2032, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Melanoma
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
  • Breast cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,( US$ Mn)
  • Head and neck cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,( US$ Mn)
  • Bladder Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,( US$ Mn)
  • Prostate Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,( US$ Mn)
  • Lung Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
  • Others (Colorectal Cancer, and among Others)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)

7. Oncolytic Virus Therapy Market, By Development Stage, 2020-2032, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Commercial
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
  • Pipeline Phase
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
  • Pre-clinical
  • Phase I
  • Phase II
  • Phase III

8. Oncolytic Virus Therapy Market , By Distribution Channel, 2020-2032, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)

9. Oncolytic Virus Therapy Market, By Region, 2020-2032, (US$ Mn)

  • Introduction
    • Market Share Analysis, By Country, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, For Country 2021-2032
    • Country Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020-2032,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Development Stage, 2020-2032,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
      • U.S.
      • Canada
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020-2032,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Development Stage, 2020-2032,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
      • U.K
      • Germany
      • France
      • Italy
      • Spain
      • Russia
      • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020-2032,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Development Stage, 2020-2032,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
      • China
      • Japan
      • India
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020-2032,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Development Stage, 2020-2032,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020-2032,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Development Stage, 2020-2032,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
      • GCC
      • Israel
      • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020-2032,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Development Stage, 2020-2032,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020-2032,(US$ Mn)
      • North Africa
      • Central Africa
      • South Africa

10. Competitive Landscape

  • Amgen Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Merck & Co., Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Oncolytics Biotech Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Circio Holding ASA
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Akamis Bio
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Vyriad, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • SillaJen Biotherapeutics
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Cold Genesys Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Sorrento Therapeutics, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Takara Bio Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Replimune Group Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Genelux Corporation
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Synthetic Biologics, Inc
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Lokon Pharma AB
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Elicera Therapeutics
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Analyst Views

11. Section

  • Research Methodology
  • About us